Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (331-340 of 347) with videos related to

Pageof 35
Sort By:
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Journal of Hematology & Oncology|April 18, 2020
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Yongping Song, Yan Qin, et al.
Cancer Biology & Medicine|December 10, 2020
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer AssociationYi Ba, Yuankai Shi, Wenqi Jiang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
British Journal of Clinical Pharmacology|November 3, 2021
Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological SocietyZaiwei Song, Yang Hu, Shuang Liu, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Frontiers in Oncology|November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in ChinaWeiping Liu, Donglu Zhao, Ting Liu, et al.
The Lancet Regional Health. Western Pacific|March 7, 2023
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 studyYuankai Shi, Xintian Qin, Xingchen Peng, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
Pageof 35

Showing results (331-340 of 347) with videos related to

Sort By:
Pageof 35
Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Journal of Hematology & Oncology|April 18, 2020
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Yongping Song, Yan Qin, et al.
Cancer Biology & Medicine|December 10, 2020
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer AssociationYi Ba, Yuankai Shi, Wenqi Jiang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2022
Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b StudyYuankai Shi, Baolan Li, Lin Wu, et al.
The Lancet. Respiratory Medicine|December 15, 2023
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trialMengzhao Wang, Yun Fan, Meili Sun, et al.
British Journal of Clinical Pharmacology|November 3, 2021
Medication therapy of high-dose methotrexate: An evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological SocietyZaiwei Song, Yang Hu, Shuang Liu, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Frontiers in Oncology|November 22, 2021
A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in ChinaWeiping Liu, Donglu Zhao, Ting Liu, et al.
The Lancet Regional Health. Western Pacific|March 7, 2023
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 studyYuankai Shi, Xintian Qin, Xingchen Peng, et al.
Nature Medicine|June 28, 2024
Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trialYuankai Shi, Wei Guo, Wei Wang, et al.
Pageof 35